In this episode, which has been initiated and funded by Britannia Pharmaceuticals, we’re looking at what it means to reach an advanced stage of the condition.
Because Parkinson’s disease is so individualised, its progression is not black and white. The term ‘advanced’ Parkinson’s generally refers to the stage at which symptoms have a bigger impact on day-to-day life. At this stage, medications may not be as effective and people with the condition may begin to rely more on care.
Our first guest is Colin Cheesman, a former local authority chief executive based in Chester, UK, who at 74 has lived with Parkinson’s disease for two decades. Colin has been able to maintain a good quality of life but in the past few years, his Parkinson’s symptoms – such as involuntary movement and loss of balance – have become more challenging.
He is joined by Dr Nishantha Silva, a geriatrician based in Grantham, UK, who has specialised in Parkinson’s disease for 10 years. As a doctor, Nishantha is motivated by the experiences of his own father, who lived with the condition – and strongly believes that the right care can ensure long, fulfilling lives for people with Parkinson’s.
Parkinson’s Life magazine is produced by Speak Media on behalf of the European Parkinson’s Disease Association, the leading voice for Parkinson’s in Europe. For the latest research and information on Parkinson’s, visit EPDA.eu.com.
If you like what you’ve heard, please do take the time to rate and review – it helps make sure others can find us! And if you’d like to get in touch, email us at email@example.com or catch up with us on Facebook (https://www.facebook.com/parkinsonslife) and Twitter (https://twitter.com/parkinsons_life)
Message from our sponsor: The content of this podcast was up to date and accurate at the time of recording in June 2021. The views expressed in this episode represent the speakers’ own opinions and experiences. Speakers may express personal opinions that are not necessarily shared by Britannia Pharmaceuticals. Content from this episode has been reviewed by Britannia to ensure compliance with the ABPI and EFPIA Codes of Practice for the Pharmaceutical Industry. Any adverse events discussed within this podcast have been reported to the regulatory authorities. All adverse events should be reported to the relevant regulatory authority.